Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2024World Journal of CardiologyOpen Access

Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMoiud MohyeldinSSShitij ShrivastavaSASai Vishnu Vardhan Allu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mohyeldin et al. (2024) studied this question.

synapsesocial.com/papers/68e68bf8b6db643587613d80https://doi.org/10.4330/wjc.v16.i5.269
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling2014 · 407 citations
  2. 2Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience2018 · 20 citations
  3. 3Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL2019 · 369 citations
  4. 4Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)2016 · 135 citations
  5. 5Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma2013 · 1,710 citations